In “Test” region 75% of women (aged 24-64) are screened regularly, meaning every 3 years. A cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 50% coverage, even if the coverage is much lower than 90%, could prevent 8 cases of cervicocarcinoma and 4 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (8,721 €/QALY).
Analisi regionale dei costi e dei benefici con il vaccino anti-HPV bivalente adiuvato con AS04 - Regione Test
GASPARINI, ROBERTO;PANATTO, DONATELLA;
2012-01-01
Abstract
In “Test” region 75% of women (aged 24-64) are screened regularly, meaning every 3 years. A cost-effectiveness analysis shows that, considering regional tariffs, the multiple cohort (12-year-old + 25-year-old women) vaccination strategy with a 50% coverage, even if the coverage is much lower than 90%, could prevent 8 cases of cervicocarcinoma and 4 related deaths more than the vaccination of only 12-year-old girls, and thus proves to be cost-effective (8,721 €/QALY).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
